Advertisement

Gene Therapy

  • Hao Wu
  • Ram I. Mahato
Chapter

Abstract

The human body is composed of a variety of proteins. Almost all human diseases are the results of improper production or function of proteins. Traditional small molecule drugs usually interact with proteins such as enzymes, hormones, and transcriptional factors to exert their therapeutic potential. However, many severe and deliberating diseases (e.g., diabetes, hemophilia, cystic fibrosis) and several chronic diseases (e.g., hypertension, ischemic heart disease, asthma, Parkinson’s disease, motor neuron disease, multiple sclerosis) remain inadequately treated by the conventional pharmaceutical approaches.

Keywords

Human Immunodeficiency Virus Gene Therapy Cystic Fibrosis Transmembrane Conductance Regulator Insertional Mutagenesis Nonviral Vector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We would like to thank the National Institutes of Health (NIH) for the financial support (R01DK69968).

References

  1. Aghi M, Martuza RL (2005) Oncolytic viral therapies - the clinical experience. Oncogene 24(52):7802–7816PubMedGoogle Scholar
  2. Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK, Philpott NJ (2007) Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 15(11):1947–1954. doi: 10.1038/sj.mt.6300281 PubMedGoogle Scholar
  3. Armentano D, Sookdeo CC, Hehir KM, Gregory RJ, St George JA, Prince GA, Wadsworth SC, Smith AE (1995) Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 6(10):1343–1353. doi: 10.1089/hum.1995.6.10-1343 PubMedGoogle Scholar
  4. Arrode-Bruses G, Sheffer D, Hegde R, Dhillon S, Liu Z, Villinger F, Narayan O, Chebloune Y (2010) Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine. J Virol 84(3):1243–1253. doi: 10.1128/JVI.01846-09 PubMedGoogle Scholar
  5. Bedouelle H, Duplay P (1988) Production in Escherichia coli and one-step purification of bifunctional hybrid proteins which bind maltose. Export of the klenow polymerase into the periplasmic space. Eur J Biochem 171(3):541–549PubMedGoogle Scholar
  6. Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus C, Accart N et al (1997) Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 8(1):15–25. doi:  10.1089/hum.1997.8.1-15 PubMedGoogle Scholar
  7. Blackburn MR, Kellems RE (2005) Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 86:1–41PubMedGoogle Scholar
  8. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G et al (1995) T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270(5235):475–480PubMedGoogle Scholar
  9. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E et al (1995) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 270(5235):470–475PubMedGoogle Scholar
  10. Boussif O, Lezoualc’h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr P (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 92(16):7297–7301PubMedGoogle Scholar
  11. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288(5466):669–672PubMedGoogle Scholar
  12. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR (1997) Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A 94(5):1645–1650PubMedGoogle Scholar
  13. Chen SH, Kosai K, Xu B, Pham-Nguyen K, Contant C, Finegold MJ, Woo SL (1996) Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 56(16):3758–3762PubMedGoogle Scholar
  14. Chillon M, Lee JH, Fasbender A, Welsh MJ (1998) Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther 5(7):995–1002. doi: 10.1038/sj.gt.3300665 PubMedGoogle Scholar
  15. Corsi K, Chellat F, Yahia L, Fernandes JC (2003) Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials 24(7):1255–1264PubMedGoogle Scholar
  16. Crook NC, Freeman ES, Alper HS (2011) Re-engineering multicloning sites for function and convenience. Nucleic Acids Res 39(14):e92. doi: 10.1093/nar/gkr346 PubMedGoogle Scholar
  17. Croyle MA, Cheng X, Wilson JM (2001) Development of formulations that enhance the physical stability of viral vectors for human gene therapy. Gene Ther 8(17):1281–1291PubMedGoogle Scholar
  18. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM (1995) Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 92(5):1401–1405PubMedGoogle Scholar
  19. Dang CV, Lee WM (1988) Identification of the human c-myc protein nuclear translocation signal. Mol Cell Biol 8(10):4048–4054PubMedGoogle Scholar
  20. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN et al (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26(36):5896–5903. doi: 10.1200/JCO.2007.15.6794 PubMedGoogle Scholar
  21. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF (2000) Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 105(11):1573–1587. doi: 10.1172/JCI8317 PubMedGoogle Scholar
  22. Dzau VJ, Gnecchi M, Pachori AS (2005) Enhancing stem cell therapy through genetic modification. J Am Coll Cardiol 46(7):1351–1353. doi: 10.1016/j.jacc.2005.07.023 PubMedGoogle Scholar
  23. Edelstein ML, Abedi MR, Wixon J, Edelstein RM (2004) Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med 6(6):597–602PubMedGoogle Scholar
  24. Erles K, Sebokova P, Schlehofer JR (1999) Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 59(3):406–411PubMedGoogle Scholar
  25. Ertl HC (2005) Challenges of immune responses in gene replacement therapy. IDrugs 8(9):736–738PubMedGoogle Scholar
  26. Fallaux FJ, et al (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Human gene therapy 9:1909–1917PubMedGoogle Scholar
  27. Fallaux FJ, van der Eb AJ, Hoeben, RC (1999) Who's afraid of replication-competent adenoviruses? Gene therapy 6:709–712PubMedGoogle Scholar
  28. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R (1996) A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 7(9):1145–1159PubMedGoogle Scholar
  29. Grayson WL, Frohlich M, Yeager K, Bhumiratana S, Chan ME, Cannizzaro C, Wan LQ, Liu XS, Guo XE, Vunjak-Novakovic G (2010) Engineering anatomically shaped human bone grafts. Proc Natl Acad Sci U S A 107(8):3299–3304. doi: 10.1073/pnas.0905439106 PubMedGoogle Scholar
  30. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348(3):255–256PubMedGoogle Scholar
  31. Hagstrom JN, Couto LB, Scallan C, Burton M, McCleland ML, Fields PA, Arruda VR, Herzog RW, High KA (2000) Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood 95(8):2536–2542PubMedGoogle Scholar
  32. High KA, Aubourg P (2011) RAAV human trial experience. Methods Mol Biol 807:429–457. doi: 10.1007/978-1-61779-370-7_18 PubMedGoogle Scholar
  33. Hofmann A, Wenzel D, Becher UM, Freitag DF, Klein AM, Eberbeck D, Schulte M et al (2009) Combined targeting of lentiviral vectors and positioning of transduced cells by magnetic nanoparticles. Proc Natl Acad Sci U S A 106(1):44–49. doi: 10.1073/pnas.0803746106 PubMedGoogle Scholar
  34. Huang C, Li M, Chen C, Yao Q (2008) Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 12(5):637–645. doi: 10.1517/14728222.12.5.637 PubMedGoogle Scholar
  35. Huang MT, Gorman CM (1990) The simian virus 40 small-t intron, present in many common expression vectors, leads to aberrant splicing. Mol Cell Biol 10(4):1805–1810PubMedGoogle Scholar
  36. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Yla-Herttuala S (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10(5):967–972. doi: 10.1016/j.ymthe.2004.08.002 PubMedGoogle Scholar
  37. Itaka K, Yamauchi K, Harada A, Nakamura K, Kawaguchi H, Kataoka K (2003) Polyion complex micelles from plasmid DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer as serum-tolerable polyplex system: physicochemical properties of micelles relevant to gene transfection efficiency. Biomaterials 24(24):4495–4506PubMedGoogle Scholar
  38. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3):535–546. doi: 10.1182/blood-2009-03-211714 PubMedGoogle Scholar
  39. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K (2009) Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458(7239):771–775. doi: 10.1038/nature07864 PubMedGoogle Scholar
  40. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 369(9579):2097–2105. doi: 10.1016/S0140-6736(07)60982-9 PubMedGoogle Scholar
  41. Karnieli O, Izhar-Prato Y, Bulvik S, Efrat S (2007) Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells 25(11):2837–2844. doi: 10.1634/stemcells.2007-0164, 2007–0164 [pii]PubMedGoogle Scholar
  42. Kim J, Chen CP, Rice KG (2005) The proteasome metabolizes peptide-mediated nonviral gene delivery systems. Gene Ther 12(21):1581–1590. doi: 10.1038/sj.gt.3302575 PubMedGoogle Scholar
  43. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME et al (1995) Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1(10):1017–1023PubMedGoogle Scholar
  44. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439–1441. doi: 10.1016/S0140-6736(04)16104-7, S0140-6736(04)16104-7 [pii]PubMedGoogle Scholar
  45. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ (1995) Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6(4):395–405. doi: 10.1089/hum.1995.6.4-395 PubMedGoogle Scholar
  46. Levine BL, Humeau LM, Boyer J, Macgregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103(46):17372–17377PubMedGoogle Scholar
  47. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK et al (2011) AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10(4):309–319. doi: 10.1016/S1474-4422(11)70039-4 PubMedGoogle Scholar
  48. Li F, Mahato RI (2009) Bipartite vectors for co-expression of a growth factor cDNA and short hairpin RNA against an apoptotic gene. J Gene Med 11(9):764–771. doi: 10.1002/jgm.1357 PubMedGoogle Scholar
  49. Li L, Li F, Qi H, Feng G, Yuan K, Deng H, Zhou H (2008) Coexpression of Pdx1 and betacellulin in mesenchymal stem cells could promote the differentiation of nestin-positive epithelium-like progenitors and pancreatic islet-like spheroids. Stem Cells Dev 17(4):815–823. doi: 10.1089/scd.2008.0060 PubMedGoogle Scholar
  50. Lochmuller H, Petrof BJ, Pari G, Larochelle N, Dodelet V, Wang Q, Allen C et al (1996) Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther 3(8):706–716PubMedGoogle Scholar
  51. Louis N, Evelegh C, Graham FL (1997) Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 233:423–429PubMedGoogle Scholar
  52. MacGregor RR (2001) Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum Gene Ther 12(16):2028–2029PubMedGoogle Scholar
  53. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA et al (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178(1):92–100PubMedGoogle Scholar
  54. Mahato RI, Rolland A, Tomlinson E (1997) Cationic lipid-based gene delivery systems: pharmaceutical perspectives. Pharm Res 14(7):853–859PubMedGoogle Scholar
  55. Mahato RI, Smith LC, Rolland A (1999) Pharmaceutical perspectives of nonviral gene therapy. Adv Genet 41:95–156PubMedGoogle Scholar
  56. Majhen D, Ambriovic-Ristov A (2006) Adenoviral vectors–how to use them in cancer gene therapy? Virus Res 119(2):121–133PubMedGoogle Scholar
  57. Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schonely K et al (2005) Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 16(1):17–25. doi: 10.1089/hum.2005.16.17 PubMedGoogle Scholar
  58. Mannisto M, Vanderkerken S, Toncheva V, Elomaa M, Ruponen M, Schacht E, Urtti A (2002) Structure-activity relationships of poly(L-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J Control Release 83(1):169–182PubMedGoogle Scholar
  59. Manthorpe M, Hobart P, Hermanson G, Ferrari M, Geall A, Goff B, Rolland A (2005) Plasmid vaccines and therapeutics: from design to applications. Adv Biochem Eng Biotechnol 99:41–92PubMedGoogle Scholar
  60. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7(10):867–874PubMedGoogle Scholar
  61. Martin ME, Rice KG (2007) Peptide-guided gene delivery. AAPS J 9(1):E18–E29. doi: 10.1208/aapsj0901003 PubMedGoogle Scholar
  62. McGinley L, McMahon J, Strappe P, Barry F, Murphy M, O’Toole D, O’Brien T (2011) Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia. Stem Cell Res Ther 2(2):12. doi: 10.1186/scrt53, scrt53 [pii]PubMedGoogle Scholar
  63. McKenzie DL, Collard WT, Rice KG (1999) Comparative gene transfer efficiency of low molecular weight polylysine DNA-condensing peptides. J Pept Res 54(4):311–318PubMedGoogle Scholar
  64. Medina-Kauwe LK (2003) Endocytosis of adenovirus and adenovirus capsid proteins. Adv Drug Deliv Rev 55(11):1485–1496PubMedGoogle Scholar
  65. Melo LG, Pachori AS, Gnecchi M, Dzau VJ (2006) Genetic therapies for cardiovascular diseases. Trends Mol Med 11(5):240–250Google Scholar
  66. Mendell JR, Miller A (2004) Gene transfer for neurologic disease: agencies, policies, and process. Neurology 63(12):2225–2232PubMedGoogle Scholar
  67. Miyata K, Kakizawa Y, Nishiyama N, Harada A, Yamasaki Y, Koyama H, Kataoka K (2004) Block catiomer polyplexes with regulated densities of charge and disulfide cross-linking directed to enhance gene expression. J Am Chem Soc 126(8):2355–2361. doi: 10.1021/ja0379666 PubMedGoogle Scholar
  68. Miyata K, Kakizawa Y, Nishiyama N, Yamasaki Y, Watanabe T, Kohara M, Kataoka K (2005) Freeze-dried formulations for in vivo gene delivery of PEGylated polyplex micelles with disulfide crosslinked cores to the liver. J Control Release 109(1–3):15–23. doi: 10.1016/j.jconrel.2005.09.043 PubMedGoogle Scholar
  69. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72(10):8150–8157PubMedGoogle Scholar
  70. Miyoshi H, Takahashi M, Gage FH, Verma IM (1997) Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A 94(19):10319–10323PubMedGoogle Scholar
  71. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F et al (2009) The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119(4):964–975. doi: 10.1172/JCI37630 PubMedGoogle Scholar
  72. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126–129. doi: 10.1126/science.1129003 PubMedGoogle Scholar
  73. Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC (2005) Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther 16(9):1065–1074PubMedGoogle Scholar
  74. Mori S, Wang L, Takeuchi T, Kanda T (2004) Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 330(2):375–383. doi: 10.1016/j.virol.2004.10.012 PubMedGoogle Scholar
  75. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese RM, Candotti F (2003) Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101(7):2563–2569PubMedGoogle Scholar
  76. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P et al (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365(25):2357–2365. doi: 10.1056/NEJMoa1108046 PubMedGoogle Scholar
  77. Nemerow GR, Stewart PL (1999) Role of av integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev 63(3):725–734PubMedGoogle Scholar
  78. Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A, Muskheli V, Pabon L, Reinecke H, Murry CE (2007) Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 21(7):1345–1357. doi: 10.1096/fj.06-6769com, fj.06-6769com [pii]PubMedGoogle Scholar
  79. Panakanti R, Mahato RI (2009) Bipartite adenoviral vector encoding hHGF and hIL-1Ra for improved human islet transplantation. Pharm Res 26(3):587–596. doi: 10.1007/s11095-008-9777-y PubMedGoogle Scholar
  80. Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, Huard J (2002) Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110(6):751–759. doi: 10.1172/JCI15153 PubMedGoogle Scholar
  81. Peng Z (2005) Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16(9):1016–1027. doi: 10.1089/hum.2005.16.1016 PubMedGoogle Scholar
  82. Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells 25(11):2896–2902. doi: 10.1634/stemcells.2007-0637 PubMedGoogle Scholar
  83. Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, Lahn BT (2010) Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One 5(5):e10611. doi: 10.1371/journal.pone.0010611 PubMedGoogle Scholar
  84. Ranga U, Woffendin C, Verma S, Xu L, June CH, Bishop DK, Nabel GJ (1998) Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A 95(3):1201–1206PubMedGoogle Scholar
  85. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80(1–2):148–158PubMedGoogle Scholar
  86. Reilly JP, Grise MA, Fortuin FD, Vale PR, Schaer GL, Lopez J, VAN Camp JR et al (2005) Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J Interv Cardiol 18(1):27–31. doi: 10.1111/j.1540-8183.2005.04026.x PubMedGoogle Scholar
  87. Rip J, Nierman MC, Sierts JA, Petersen W, Van den Oever K, Van Raalte D, Ross CJ et al (2005) Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther 16(11):1276–1286. doi: 10.1089/hum.2005.16.1276 PubMedGoogle Scholar
  88. Roth JA, Cristiano RJ (1997) Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89(1):21–39PubMedGoogle Scholar
  89. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A (2005) Spontaneous human adult stem cell transformation. Cancer Res 65(8):3035–3039, 65/8/3035 [pii]PubMedGoogle Scholar
  90. Ryu WS, Mertz JE (1989) Simian virus 40 late transcripts lacking excisable intervening sequences are defective in both stability in the nucleus and transport to the cytoplasm. J Virol 63(10):4386–4394PubMedGoogle Scholar
  91. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H et al (2000) Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11(16):2197–2205. doi: 10.1089/104303400750035726 PubMedGoogle Scholar
  92. Schuldiner M, Itskovitz-Eldor J, Benvenisty N (2003) Selective ablation of human embryonic stem cells expressing a “suicide” gene. Stem Cells 21(3):257–265. doi: 10.1634/stemcells.21-3-257 PubMedGoogle Scholar
  93. Shirakawa T (2009) Clinical trial design for adenoviral gene therapy products. Drug News Perspect 22(3):140–145. doi: 10.1358/dnp.2009.22.3.1354090 PubMedGoogle Scholar
  94. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S et al (2010) Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18(3):643–650. doi: 10.1038/mt.2009.277 PubMedGoogle Scholar
  95. Simons JW, Sacks N (2006) Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 24(5):419–424PubMedGoogle Scholar
  96. Singh S, Narang AS, Mahato RI (2011) Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res 28(12):2996–3015. doi: 10.1007/s11095-011-0608-1 PubMedGoogle Scholar
  97. Spilianakis CG, Lalioti MD, Town T, Lee GR, Flavell RA (2005) Interchromosomal associations between alternatively expressed loci. Nature 435(7042):637–645. doi: 10.1038/nature03574 PubMedGoogle Scholar
  98. Springer ML (2006) A balancing act: therapeutic approaches for the modulation of angiogenesis. Curr Opin Investig Drugs 7(3):243–250PubMedGoogle Scholar
  99. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F et al (2006) Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 13(21):1503–1511. doi: 10.1038/sj.gt.3302802 PubMedGoogle Scholar
  100. Stewart PL, Chiu CY, Huang S, Muir T, Zhao Y, Chait B, Mathias P, Nemerow GR (1997) Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO J 16(6):1189–1198. doi: 10.1093/emboj/16.6.1189 PubMedGoogle Scholar
  101. Stolberg SG (1999) The biotech death of Jesse Gelsinger. N Y Times Mag 136–140:149–150Google Scholar
  102. Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K, Natsoulis G (1997) Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 71(10):7951–7959PubMedGoogle Scholar
  103. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R (1999) Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17(22):2826–2829PubMedGoogle Scholar
  104. Tsuda H, Wada T, Ito Y, Uchida H, Dehari H, Nakamura K, Sasaki K, Kobune M, Yamashita T, Hamada H (2003) Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. Mol Ther 7(3):354–365PubMedGoogle Scholar
  105. Tuszynski MH, Thal L, Pay M, Salmon DP, HS U, Patel P et al (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11(5):551–555. doi: 10.1038/nm1239 PubMedGoogle Scholar
  106. U.S. Department of Health and Human Services (1998) Guidance for industry: guidance for human somatic cell therapy and gene therapy. Center for Biologics Evaluation and Research, United States Food and Drug Administration, Rockville, MDGoogle Scholar
  107. Uckert W, Kammertons T, Haack K, Qin Z, Gebert J, Schendel DJ, Blankenstein T (1998) Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 9(6):855–865. doi: 10.1089/hum.1998.9.6-855 PubMedGoogle Scholar
  108. Varghese S, Rabkin SD (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9(12):967–978PubMedGoogle Scholar
  109. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M et al (2011) In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6(5):e19252. doi: 10.1371/journal.pone.0019252 PubMedGoogle Scholar
  110. Verma IM (1990) Gene therapy. Sci Am 263(5):68–72, 81–64PubMedGoogle Scholar
  111. Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H (2007) Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med 1(1):74–79. doi: 10.1002/term.8 PubMedGoogle Scholar
  112. Wang DA, Narang AS, Kotb M, Gaber AO, Miller DD, Kim SW, Mahato RI (2002) Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules 3(6):1197–1207PubMedGoogle Scholar
  113. Weber W, Fussenegger M (2006) Pharmacologic transgene control systems for gene therapy. J Gene Med 8(5):535–556PubMedGoogle Scholar
  114. Wells DJ (2004) Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther 11(18):1363–1369. doi: 10.1038/sj.gt.3302337 PubMedGoogle Scholar
  115. Wiley (2012) The Journal of Gene Medicine Clinical Trials Worldwide Database http://www.wiley.co.uk/genetherapy/clinical/. Accessed 3 Mar 2012
  116. Wright JF, Qu G, Tang C, Sommer JM (2003) Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Devel 6(2):174–178PubMedGoogle Scholar
  117. Wu H, Yoon AR, Li F, Yun CO, Mahato RI (2011) RGD peptide-modified adenovirus expressing HGF and XIAP improves islet transplantation. J Gene Med. doi: 10.1002/jgm.1626 Google Scholar
  118. Wu Z, Asokan A, Samulski RJ (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14(3):316–327PubMedGoogle Scholar
  119. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y et al (2004) Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23(12):1666–1670PubMedGoogle Scholar
  120. Xu ZL, Mizuguchi H, Sakurai F, Koizumi N, Hosono T, Kawabata K, Watanabe Y, Yamaguchi T, Hayakawa T (2005) Approaches to improving the kinetics of adenovirus-delivered genes and gene products. Adv Drug Deliv Rev 57(5):781–802PubMedGoogle Scholar
  121. Yan Z, Zhang Y, Duan D, Engelhardt JF (2000) Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A 97(12):6716–6721PubMedGoogle Scholar
  122. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA (2002) Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76(9):4580–4590PubMedGoogle Scholar
  123. Zhao T, Zhang ZN, Rong Z, Xu Y (2011) Immunogenicity of induced pluripotent stem cells. Nature 474(7350):212–215. doi: 10.1038/nature10135 PubMedGoogle Scholar
  124. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72(12):9873–9880PubMedGoogle Scholar
  125. Zwaka T (2006) Use of genetically modified stem cells in experimental gene therapies. In: Regenerative medicine. National Institutes of Health, BethesdaGoogle Scholar

Further Reading

  1. Schleef M et al. (2001) Plasmids for therapy cbrsand vaccination. Wiley-VCH, New York, NYGoogle Scholar
  2. Schleef M (2005) DNA pharmaceuticals: formulation and delivery in gene therapy, DNA vaccination and immunotherapy. John Wiley & Sons, HobokenGoogle Scholar
  3. National Institutes of Health (2006) Regenerative medicine. National Institutes of Health, Bethesda, DCGoogle Scholar
  4. Narang A, Mahato RI (2010) Targeted delivery of small and macromolecular drugs. CRC press, Boca Raton, FLGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesUniversity of Tennessee Health Science CenterMemphisUSA
  2. 2.Department of Pharmaceutical Sciences, College of PharmacyUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations